pink eye

Showing 1 posts of 1 posts found.

Shire building

Shire in $300m Foresight acquisition

August 4, 2015
Manufacturing and Production, Research and Development, Sales and Marketing FST-100, Foresight Biotherapeutics, Shire, conjunctivitis, dry eye, lifitegrast, pink eye

Shire has acquired Foresight Biotherapeutics for $300 million, as it looks to build its presence in eye diseases. The acquisition …

The Gateway to Local Adoption Series

Latest content